Biomarkers of Neutrophil Activation in Patients with Symptomatic Chronic Peripheral Artery Disease Predict Worse Cardiovascular Outcome.

Details

Ressource 1Download: biomedicines-11-00866-v2.pdf (1579.05 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_D7E8BC8BB08F
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Biomarkers of Neutrophil Activation in Patients with Symptomatic Chronic Peripheral Artery Disease Predict Worse Cardiovascular Outcome.
Journal
Biomedicines
Author(s)
Buso G., Faggin E., Bressan A., Galliazzo S., Cinetto F., Felice C., Fusaro M., Erdmann A., Pauletto P., Rattazzi M., Mazzolai L.
ISSN
2227-9059 (Print)
ISSN-L
2227-9059
Publication state
Published
Issued date
12/03/2023
Peer-reviewed
Oui
Volume
11
Number
3
Pages
866
Language
english
Notes
Publication types: Journal Article
Publication Status: epublish
Abstract
Neutrophils play a role in cardiovascular (CV) disease. However, relatively scant evidence exists in the setting of peripheral artery disease (PAD). The aims of this study were to measure biomarkers of neutrophil activation in patients with symptomatic chronic PAD compared with healthy controls, to assess their association with PAD severity, and to evaluate their prognostic value in patients with PAD. The following circulating markers of neutrophil degranulation were tested: polymorphonuclear neutrophil (PMN) elastase, neutrophil gelatinase-associated lipocalin (NGAL), and myeloperoxidase (MPO). Neutrophil extracellular traps (NETs) were quantified by measuring circulating MPO-DNA complexes. Patients with PAD underwent a comprehensive series of vascular tests. The occurrence of 6-month major adverse CV (MACE) and limb events (MALE) was assessed. Overall, 110 participants were included, 66 of which had PAD. After adjustment for conventional CV risk factors, PMN-elastase (adjusted odds ratio [OR]: 1.008; 95% confidence interval [CI]: 1.002-1.015; p = 0.006), NGAL (adjusted OR: 1.045; 95%CI: 1.024-1.066; p < 0.001), and MPO (adjusted OR: 1.013; 95%CI: 1.001-1.024; p = 0.028) were significantly associated with PAD presence. PMN-elastase (adjusted hazard ratio [HR]: 1.010; 95%CI: 1.000-1.020; p = 0.040) and MPO (adjusted HR: 1.027; 95%CI: 1.004-1.051; p = 0.019) were predictive of 6-month MACE and/or MALE. MPO displayed fair prognostic performance on receiver operating characteristic (ROC) curve analyses, with an area under the curve (AUC) of 0.74 (95%CI: 0.56-0.91) and a sensitivity and specificity of 0.80 and 0.65, respectively, for a cut-off of 108.37 ng/mL. MPO-DNA showed a weak inverse correlation with transcutaneous oximetry (TcPO2) on proximal foot (adjusted ρ -0.287; p = 0.032). In conclusion, in patients with symptomatic chronic PAD, enhanced neutrophil activity may be associated with an increased risk of acute CV events, rather than correlate with disease severity. Further research is needed to clarify the role of neutrophils in PAD natural history.
Keywords
biomarkers, myeloperoxidase, neutrophil degranulation, neutrophil extracellular traps, peripheral artery disease
Pubmed
Web of science
Open Access
Yes
Create date
03/04/2023 10:32
Last modification date
08/08/2024 6:25
Usage data